MHRAsafety guidance72% confidence
Opportunities for patients and the public to be involved in the work of the MHRA
Source: MHRA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Avidity Biosciences.
Regulatory Analysis
How we engage and involve patients and the public in our regulatory decision-making.
Supporting Context
- Therapeutic area
- Neurology · Duchenne Muscular Dystrophy
- Sub-indication
- General
Related signal: Managed Access Program for Del-zota in DMD Patients Announced by Avidity Biosciences